PDF(Pubmed)
Abstract：
The gut microbiota is a complex ecosystem that has coevolved with the human body for hundreds of millions of years. In the past 30 years, with the progress of gene sequencing and omics technology, the research related to gut microbiota has developed rapidly especially in the field of digestive system diseases and systemic metabolic diseases. Mechanical, biological, immune, and other factors make the intestinal flora form a close bidirectional connection with the liver and gallbladder, which can be called the \"gut-liver-biliary axis.\" Liver and gallbladder, as internal organs of the peritoneum, suffer from insidious onset, which are not easy to detect. The diagnosis is often made through laboratory chemical tests and imaging methods, and intervention measures are usually taken only when organic lesions have occurred. At this time, some people may have entered the irreversible stage of disease development. We reviewed the literature describing the role of intestinal flora in the pathogenesis and biotherapy of hepatobiliary diseases in the past 3-5 years, including the dynamic changes of intestinal flora at different stages of the disease, as well as the signaling pathways involved in intestinal flora and its metabolites, etc. After summarizing the above contents, we hope to highlight the potential of intestinal flora as a new clinical target for early prevention, early diagnosis, timely treatment and prognosis of hepatobiliary diseases. GRAPHICAL ABSTRACT.
摘要：
肠道微生物群是一个复杂的生态系统，与人体共进化了数亿年。在过去的30年里,随着基因测序和组学技术的进步,尤其是在消化系统疾病和系统代谢性疾病领域,与肠道菌群相关的研究发展迅速。机械,生物，免疫，等因素使肠道菌群与肝胆形成密切的双向联系,这可以称为“肠-肝-胆轴”。“肝脏和胆囊，作为腹膜的内脏器官，患有阴险的发作，不容易被发现。诊断通常通过实验室化学检查和成像方法进行，通常仅在发生器质性病变时才采取干预措施。此时,有些人可能已经进入了疾病发展的不可逆转阶段。我们回顾了在过去3-5年中描述肠道菌群在肝胆疾病的发病机制和生物治疗中的作用的文献。包括疾病不同阶段肠道菌群的动态变化，以及涉及肠道菌群及其代谢产物的信号通路，等。在总结上述内容后，我们希望强调肠道菌群作为早期预防的新临床目标的潜力，早期诊断,肝胆疾病的及时治疗和预后。图形摘要。
